- Home
- ACHV vs MNOV Comparison
ACHV vs MNOV Comparison
Compare ACHV & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACHV
- MNOV
- Stock Information
- Founded
- ACHV N/A
- MNOV 2000
- Country
- ACHV Canada
- MNOV United States
- Employees
- ACHV N/A
- MNOV N/A
- Industry
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- MNOV Biotechnology: Pharmaceutical Preparations
- Sector
- ACHV Health Care
- MNOV Health Care
- Exchange
- ACHV Nasdaq
- MNOV Nasdaq
- Market Cap
- ACHV 72.5M
- MNOV 76.5M
- IPO Year
- ACHV N/A
- MNOV 2005
- Fundamental
- Price
- ACHV $2.35
- MNOV $1.47
- Analyst Decision
- ACHV Strong Buy
- MNOV Strong Buy
- Analyst Count
- ACHV 3
- MNOV 1
- Target Price
- ACHV $14.33
- MNOV $9.00
- AVG Volume (30 Days)
- ACHV 178.2K
- MNOV 9.6K
- Earning Date
- ACHV 05-13-2025
- MNOV 05-16-2025
- Dividend Yield
- ACHV N/A
- MNOV N/A
- EPS Growth
- ACHV N/A
- MNOV N/A
- EPS
- ACHV N/A
- MNOV N/A
- Revenue
- ACHV N/A
- MNOV N/A
- Revenue This Year
- ACHV N/A
- MNOV N/A
- Revenue Next Year
- ACHV N/A
- MNOV N/A
- P/E Ratio
- ACHV N/A
- MNOV N/A
- Revenue Growth
- ACHV N/A
- MNOV N/A
- 52 Week Low
- ACHV $1.84
- MNOV $1.12
- 52 Week High
- ACHV $5.59
- MNOV $2.55
- Technical
- Relative Strength Index (RSI)
- ACHV 46.09
- MNOV 48.15
- Support Level
- ACHV $2.32
- MNOV $1.46
- Resistance Level
- ACHV $2.69
- MNOV $1.55
- Average True Range (ATR)
- ACHV 0.18
- MNOV 0.06
- MACD
- ACHV 0.02
- MNOV 0.00
- Stochastic Oscillator
- ACHV 17.07
- MNOV 25.00
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.